SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.

Automated summary

Gastrointestinal stromal tumor (GIST) is a common malignant neoplasm of mesenchymal origin, and a successful model for targeted cancer therapies. The use of tyrosine kinase inhibitors targeting KIT/PDGFRA has greatly improved survival in both localized and advanced stages, despite previous resistance to systemic therapies. These guidelines, developed by the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS), provide an updated consensus for diagnosing and treating GIST patients, emphasizing the importance of multidisciplinary teams in specialized centers.